Pharmaceutical company Enesi Pharma, a developer of unique injectable solid dose vaccine products, revealed on Monday that it has appointed internationally recognised vaccine and infectious disease expert Dr Steven Chatfield to its Scientific Advisory Board (SAB).
The company said Dr Chatfield has nearly 40 years' experience in R&D, executive, board and advisory roles across several of public and private healthcare organisations focused on vaccines and infectious diseases.
Currently, Dr Chatfield is a non-executive director of the Vaccines Manufacturing & Innovation Centre (VMIC), a new purpose-built, state-of-the-art facility in Oxford, UK. This new centre enables academic and industry collaboration on the development, design and manufacture of vaccines.
Dr Chatfield is also a Director of the UK Cell and Gene Therapy Catapult and a member of the Scientific Advisory Board of the Jenner Institute at the University of Oxford, as well as chairman of Prokarium Ltd, a UK company that develops oral vaccine products for infectious diseases and cancer.
Earlier, Dr Chatfield was chief scientific officer and executive vice president of global vaccine business Strategic Investments for Emergent BioSolutions and was also president and CEO of its UK operation. Additionally, he was a director of Vaccitech, a private UK vaccine specialist and a director of the Centre for Emergency Preparedness and Response at the UK Health Protection Agency (now Public Health England).
In addition, Dr Chatfield has published over 100 publications on the molecular basis of pathogenicity of bacterial and viral infections and work directed towards the development of novel vaccines and immunotherapeutics, being a named inventor on 20 patents.
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer
Oxford Biomedica to acquire ABL Europe
RedHill Biopharma granted five years' market exclusivity for Talicia by US FDA
SK bioscience signs development licensing agreement with Hilleman Laboratories
Poolbeg Pharma expands patent portfolio with Immunomodulator II approval in Japan
NeoImmuneTech's NT-I7 receives US FDA Orphan Drug Designation